Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
{{output}}
Background: Market access stakeholders consider the adoption of Managed Entry Agreements (MEAs), however a clearly described methodology to quantify their implementation burden is not available in the public domain. Objective: To quantify the cost of implement... ...
